Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov purchased 25,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were acquired at an average price of C$3.87 per share, for a total transaction of C$96,840.00.
Rostislav Christov Raykov also recently made the following trade(s):
- On Thursday, December 5th, Rostislav Christov Raykov purchased 796 shares of Fennec Pharmaceuticals stock. The stock was bought at an average cost of C$8.52 per share, with a total value of C$6,779.05.
- On Wednesday, October 2nd, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$6.67, for a total value of C$16,212.34.
Fennec Pharmaceuticals Trading Up 4.0 %
FRX traded up C$0.34 during trading on Monday, reaching C$8.91. 3,395 shares of the stock traded hands, compared to its average volume of 2,022. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The stock's 50-day moving average is C$7.19 and its 200 day moving average is C$7.67. Fennec Pharmaceuticals Inc. has a 12 month low of C$5.65 and a 12 month high of C$15.43. The stock has a market capitalization of C$243.78 million, a PE ratio of 89.10 and a beta of 0.25.
Analyst Ratings Changes
Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th.
Read Our Latest Stock Report on Fennec Pharmaceuticals
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
